Register/Activate Login Contact us

Progestogen-only Pills

Filter Standards and Guidance documents

FSRH Clinical Guideline: Progestogen-only Pills (August 2022, Amended July 2023)

17 July 2023

This guideline provides evidence-based recommendations and good practice points for health professionals on the use of progestogen-only contraceptive pills. It is intended for any health care professional or health service providing contraceptive care in the UK.

Please read this guidance document in conjunction with any relevant clinical statements for this topic:

FSRH CEU Statement: Response to new study by Meaidi et al (2023) Venous thromboembolism with use of hormonal contraception and non-steroidal anti-inflammatory drugs (September 2023)

FSRH Response to new study on use of CHC and POC and breast cancer risk (March 2023)

FSRH CEU Response to published study: Maternal use of hormonal contraception and risk of childhood leukemia: a nationwide, populate-based cohort study (September 2018)

FSRH CEU Statement: Oral Contraceptives and Multiple Sclerosis (March 2014)

FSRH CEU Statement to published systematic review: The relationship between progestin hormonal contraception and depression: a systematic review (March 2018)

FSRH CEU Statement: Response to Study Contemporary Hormonal Contraception and the Risk of Breast Cancer (December 2017)

FSRH CEU Statement: Contraception and Weight Gain (August 2019)

Also available in digital format on the BMJ website: FSRH Guideline (August 2022) Progestogen-only Pills. BMJ Sexual & Reproductive Health 2022; 48:Suppl 1.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH Guideline: Progestogen-only Pills (August 2022, Amended July 2023) (Evidence relocated)

17 July 2023

This guideline provides evidence-based recommendations and good practice points for health professionals on the use of progestogen-only contraceptive pills. It is intended for any healthcare professional or health service providing contraceptive care in the UK. In this version of the POP Guideline, the supporting evidence for the recommendations has been removed from the main text and located in an appendix for ease of reading. This document is available to FSRH members and candidates only. 

This resource is available to members/candidates of FSRH.

Login

This document is up-to-date

FSRH CEU Guidance: Progestogen-only Pills Quick Reference Summary (August 2022, updated July 2023)

17 July 2023

This summary has been written as a quick reference guide to help busy clinicians to give clear, safe advice on progestogen-only contraceptive pills. Please refer to the full 2022 FSRH Progestogen-only Pills Clinical Guideline for further information and supporting evidence for this advice. This document is written for FSRH members and requires you to log in to access it.

This resource is available to members/candidates of FSRH.

Login

This document is up-to-date

FSRH Guideline-related CPD Q&A: Progestogen-only Pills (August 2022)

23 August 2022

Login to view this document. 1 CPD credit can be claimed for reading the guidance. 1 CPD credit can be claimed for answering the questions.

This resource is available to members/candidates of FSRH.

Login

This document is up-to-date

FSRH Clinical Statement - DSG-POP as Pharmacy Medication

21 July 2021

This FSRH Statement reviews two desogestrel 75mcg progestogen-only pill (POP) available over-the-counter as Pharmacy Medicines.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

< Back to Standards & Guidance